Nascent Biotech, Inc. (OTCMKTS:NBIO – Get Free Report) crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $0.03 and traded as low as $0.01. Nascent Biotech shares last traded at $0.01, with a volume of 24,200 shares traded.
Nascent Biotech Stock Performance
The business’s 50 day simple moving average is $0.03 and its two-hundred day simple moving average is $0.05.
About Nascent Biotech
Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.
Further Reading
- Five stocks we like better than Nascent Biotech
- Short Selling: How to Short a Stock
- 3 Stocks With Robust Growth Outlooks Insiders Are Buying
- How Investors Can Find the Best Cheap Dividend Stocks
- Buffett’s Billion-Dollar Bet: Will Constellation Brands Pay Off?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Dutch Bros: Percolating Higher on Hypergrowth, More Upside to Go
Receive News & Ratings for Nascent Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nascent Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png&h=45&w=95&zc=2){kind=logo}
